PCOS Is a Metabolic Condition, Not Just a Hormone Disorder
Polycystic ovary syndrome (PCOS) affects an estimated 10% of women of reproductive age and is the most common cause of anovulatory infertility. The conventional understanding frames it as a reproductive hormone disorder — elevated androgens, irregular periods, polycystic ovaries on ultrasound. The more contemporary understanding, supported by two decades of research, is that PCOS is fundamentally a metabolic condition with reproductive consequences. The androgens are a downstream effect of insulin resistance, hyperinsulinaemia, and the metabolic dysregulation that characterises the condition.
The Insulin-Androgen Connection
Hyperinsulinaemia drives androgen production in theca cells of the ovary through two mechanisms. First, insulin stimulates LH (luteinising hormone) secretion from the pituitary, increasing the stimulus for androgen production in the ovary. Second, insulin inhibits the hepatic production of sex hormone-binding globulin (SHBG), the protein that carries androgens in blood. With less SHBG, more free androgens are available to exert effects on hair follicles, skin, and the hypothalamus. This means that for a given testosterone level, the free androgen index is higher in insulin-resistant women with PCOS than in women with normal insulin sensitivity.
The practical implication is that the most effective treatments for PCOS are metabolic rather than hormonal. Inositols — specifically myo-inositol and D-chiro-inositol — improve insulin sensitivity, reduce hyperinsulinaemia, and as a downstream effect reduce androgen levels, restore ovulatory function, and improve fertility outcomes. Berberine, the botanical compound with demonstrated insulin-sensitising activity, has shown comparable effects to metformin in PCOS patients with the advantage of better tolerability and additional lipid-improving effects.
PCOS and the Gut Microbiome
The gut microbiome in PCOS patients shows characteristic differences from healthy controls — reduced diversity, altered Firmicutes-to-Bacteroidetes ratios, and decreased bacterial production of short-chain fatty acids. This dysbiosis is thought to contribute to the metabolic dysfunction of PCOS through multiple mechanisms: increased intestinal permeability leading to endotoxin translocation, altered bile acid metabolism, and reduced SCFA production. Probiotic and prebiotic interventions have shown preliminary evidence for improving both metabolic and reproductive outcomes in PCOS.
What You Can Do Today
If you have PCOS diagnosed or strongly suspected, the metabolic approach is the evidence-based first-line treatment. Inositols at 2-4g daily (myo-inositol preferred over D-chiro for most patients) improve insulin sensitivity, reduce androgens, and restore ovulatory function within 3-6 months in most women. Berberine at 1000-1500mg daily is an effective alternative for those who do not tolerate inositols. Dietary strategies — low-glycaemic-load diets, adequate protein, Mediterranean-pattern eating — support the metabolic approach alongside supplementation.
Beyond Inositols: The Full PCOS Protocol
Inositols are the first-line nutritional intervention for PCOS, but a comprehensive approach addresses multiple upstream mechanisms simultaneously. Myo-inositol at 2g twice daily improves insulin sensitivity and reduces hyperinsulinaemia. D-chiro-inositol at 25mg daily (lower dose, different mechanism) complements myo-inositol’s effects on ovarian function. Berberine at 500mg twice daily adds AMPK activation and additional insulin sensitisation. These three compounds together address the core metabolic dysfunction of PCOS more effectively than any single intervention.
Dietary modification is equally critical. A low-glycaemic-load Mediterranean-pattern diet reduces postprandial glucose spikes, lowering the insulin stimulus for ovarian androgen production. Protein intake of 1.2-1.5g per kg bodyweight supports the hormone-binding proteins that reduce free androgen levels. Elimination of dairy (which contains anabolic steroid hormones that may affect ovarian function) and reduction of refined carbohydrates completes the dietary approach.
PCOS and Mental Health
The psychological burden of PCOS — infertility, hirsutism, acne, weight management challenges — produces significantly elevated rates of anxiety, depression, and disordered eating compared to age-matched women without PCOS. The insulin-androgen axis dysregulation may contribute directly to these mental health outcomes through the effects of insulin resistance on neurotransmitter function and the blood-brain barrier. Addressing the metabolic dysfunction of PCOS frequently improves mood, energy, and cognitive function alongside the reproductive and dermatological outcomes.
What You Can Do Today
If you suspect PCOS based on irregular cycles, hirsutism, acne, or fertility challenges, request the following investigations: fasting insulin and glucose (or HbA1c), total and free testosterone, DHEA-S, and androstenedione. Transvaginal ultrasound for polycystic ovarian morphology completes the diagnostic workup. The metabolic approach — inositols, berberine, dietary modification, and exercise — is first-line and should precede pharmaceutical interventions unless symptoms are severe.
Ready to support your health? Browse supplements on Gumroad — buy now from £8.
PCOS Diagnosis: The Rotterdam Criteria
The Rotterdam criteria require two of three: oligo/anovulation (irregular or absent periods), clinical or biochemical hyperandrogenism (hirsutism, acne, or elevated androgens), and polycystic ovarian morphology on ultrasound. This means not all women with PCOS have polycystic ovaries on ultrasound — some have anovulation and hyperandrogenism without the characteristic ovarian appearance. The clinical phenotype matters for treatment: women with the metabolic phenotype (obesity, insulin resistance, dyslipidaemia) carry higher cardiovascular risk and respond better to insulin-sensitising interventions. The anovulatory phenotype may respond more to cyclical hormone therapy and targeted fertility treatment.
Inositol: The First-Line Supplement
Myo-inositol at 2g twice daily (4g total) is the most evidence-based regimen for PCOS, with consistent improvements in insulin sensitivity, ovulation frequency, and androgen levels. The combination of myo-inositol with D-chiro-inositol (in a 40:1 ratio) may be more effective than myo-inositol alone. The safety profile is excellent — the main side effects are gastrointestinal (mild nausea) at high doses, minimised by taking with meals and titrating slowly. Inositol is increasingly included in standard PCOS management protocols alongside lifestyle intervention as the foundation of pharmacological treatment.
Leave a Reply